|
Sign In to gain access to subscriptions and/or personal tools.
|
The role of MRI as a surrogate outcome measure in multiple sclerosis
H F McFarland
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA, mcfarlandh{at}ninds.nih.gov
F Barkhof
MD-MR Centre, Department of Radiology Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
J Antel
Department of Neurology, Montreal Neurological Institute, Montreal, Quebec, Canada
D H Miller
NMR Research Unit, Institute of Neurology, Queens Square, London, UK
The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-controlled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease. The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration.
Key Words: mri • outcome measure
Multiple Sclerosis, Vol. 8, No. 1,
40-51 (2002)
DOI: 10.1191/1352458502ms767xx
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
I I Kirov, V Patil, J S Babb, H Rusinek, J Herbert, and O Gonen
MR spectroscopy indicates diffuse multiple sclerosis activity during remission
J. Neurol. Neurosurg. Psychiatry,
December 1, 2009;
80(12):
1330 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Tovar-Moll, I.E. Evangelou, A.W. Chiu, N.D. Richert, J.L. Ostuni, J.M. Ohayon, S. Auh, M. Ehrmantraut, S.L. Talagala, H.F. McFarland, et al.
Thalamic Involvement and Its Impact on Clinical Disability in Patients with Multiple Sclerosis: A Diffusion Tensor Imaging Study at 3T
AJNR Am. J. Neuroradiol.,
August 1, 2009;
30(7):
1380 - 1386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Hutchinson
Predicting and preventing the future: actively managing multiple sclerosis
Practical Neurology,
June 1, 2009;
9(3):
133 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Khaleeli, D. R. Altmann, M. Cercignani, O. Ciccarelli, D. H. Miller, and A. J. Thompson
Magnetization Transfer Ratio in Gray Matter: A Potential Surrogate Marker for Progression in Early Primary Progressive Multiple Sclerosis
Arch Neurol,
November 1, 2008;
65(11):
1454 - 1459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses
Multiple Sclerosis,
July 1, 2008;
14(6):
770 - 778.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G R Davies, A Hadjiprocopis, D R Altmann, D T Chard, C M Griffin, W Rashid, G J Parker, P S Tofts, R Kapoor, A J Thompson, et al.
Normal-appearing grey and white matter T1 abnormality in early relapsing-remitting multiple sclerosis: a longitudinal study
Multiple Sclerosis,
March 1, 2007;
13(2):
169 - 177.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, E. W. Radue, et al.
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
N. Engl. J. Med.,
September 14, 2006;
355(11):
1124 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Gupta, J M Solomon, T A Tasciyan, M M Cao, R D Stone, J L Ostuni, J M Ohayon, P A Muraro, J A Frank, N D Richert, et al.
Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis
Multiple Sclerosis,
December 1, 2005;
11(6):
658 - 668.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Sastre-Garriga, G. T. Ingle, M. Rovaris, N. Tellez, B. Jasperse, D. R. Altmann, B. Benedetti, V. L. Stevenson, M. Cercignani, S. M. Leary, et al.
Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data
Neurology,
August 23, 2005;
65(4):
633 - 635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E Walker, S. N Giri, and S. B Margolin
A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis
Multiple Sclerosis,
April 1, 2005;
11(2):
149 - 158.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. H Polman, J. S Wolinsky, and S. C Reingold
Multiple sclerosis diagnostic criteria: three years later
Multiple Sclerosis,
February 1, 2005;
11(1):
5 - 12.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V L Stevenson, G T Ingle, D H Miller, and A J Thompson
Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study
Multiple Sclerosis,
August 1, 2004;
10(4):
398 - 401.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Schmidt, Ph. Scheltens, T. Erkinjuntti, L. Pantoni, H. S. Markus, A. Wallin, F. Barkhof, and F. Fazekas
White matter lesion progression: A surrogate endpoint for trials in cerebral small-vessel disease
Neurology,
July 13, 2004;
63(1):
139 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G R Davies, L Ramio-Torrenta, A Hadjiprocopis, D T Chard, C M B Griffin, W Rashid, G J Barker, R Kapoor, A J Thompson, and D H Miller
Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
July 1, 2004;
75(7):
998 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bielekova and R. Martin
Development of biomarkers in multiple sclerosis
Brain,
July 1, 2004;
127(7):
1463 - 1478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wuerfel, J. Bellmann-Strobl, P. Brunecker, O. Aktas, H. McFarland, A. Villringer, and F. Zipp
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study
Brain,
January 1, 2004;
127(1):
111 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. T. Ingle, V. L. Stevenson, D. H. Miller, and A. J. Thompson
Primary progressive multiple sclerosis: a 5-year clinical and MR study
Brain,
November 1, 2003;
126(11):
2528 - 2536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Sormani, P. Bruzzi, K. Beckmann, K. Wagner, D. H. Miller, L. Kappos, and M. Filippi
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN {beta}-1b
Neurology,
May 13, 2003;
60(9):
1462 - 1466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S.Y. Li, J. Regal, B. J. Soher, L. J. Mannon, R. I. Grossman, and O. Gonen
Brain Metabolite Profiles of T1-Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis
AJNR Am. J. Neuroradiol.,
January 1, 2003;
24(1):
68 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J Thompson
Developing clinical outcome measures in multiple sclerosis: an evolving process
Multiple Sclerosis,
October 1, 2002;
8(5):
357 - 358.
[PDF]
|
|
|
|
|
